The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Gene/protein verification
- Identity: The target is human GLRX3 (also known as PICOT/TXNL2), a cytosolic multidomain monothiol glutaredoxin. Recent structural and native mass spectrometry work on human GLRX3 confirms two Grx domains and cytosolic function, with specific complex formation with BOLA2; domain organization aligns with CGFS-type monothiol glutaredoxins having thioredoxin-like and Grx domains (supporting the UniProt domain annotations and synonym PICOT) (bargagna2024molecularpathwaysfora pages 120-124, bargagna2024molecularpathwaysfor pages 120-124, silva2023newperspectiveson pages 9-10).

1) Key concepts and definitions
- Monothiol glutaredoxin: GLRX3 is a CGFS-type monothiol glutaredoxin with two Grx domains that bind and traffic iron–sulfur (Fe–S) clusters in the cytosol, often in complexes with BOLA family proteins (BOLA2 in humans) (bargagna2024molecularpathwaysfora pages 120-124, silva2023newperspectiveson pages 9-10). In human cells, apo-GLRX3 associates with two BOLA2 molecules; upon Fe–S loading, GLRX3–BOLA2 can carry [2Fe–2S] clusters, and GLRX3 can also form [2Fe–2S]-bridged GLRX3 homodimers (bargagna2024molecularpathwaysfora pages 120-124, bargagna2024molecularpathwaysfor pages 120-124, bargagna2024molecularpathwaysfora pages 128-132).
- Cytosolic Fe–S biogenesis vs. CIA: Eukaryotic Fe–S biogenesis uses mitochondrial ISC machinery and the cytosolic CIA system. Recent in vivo work (yeast and human) shows cytosolic [2Fe–2S] protein maturation requires the mitochondrial ISC system, ABCB7/Atm1 exporter, and glutathione (GSH), but proceeds independently of the CIA machinery and of cytosolic monothiol glutaredoxins; in contrast, [4Fe–4S] maturation in the cytosol/nucleus requires ISC, ABCB7, GSH, and CIA (PNAS 2024) (https://doi.org/10.1073/pnas.2400740121; May 2024) (braymer2024requirementsforthe pages 9-10).

2) Biochemical function and pathway placement
- Cluster binding states and partners: Human GLRX3 assembles into two principal holo-states: (i) a [2Fe–2S]2–GLRX3 homodimer (two clusters, dimeric GLRX3 with GSH ligation) and (ii) a GLRX3–BOLA2 heterocomplex carrying [2Fe–2S] clusters (bargagna2024molecularpathwaysfora pages 120-124, bargagna2024molecularpathwaysfor pages 120-124). Native MS and spectroscopic studies directly observed these states and their stoichiometries (bargagna2024molecularpathwaysfora pages 120-124, bargagna2024molecularpathwaysfor pages 120-124).
- Cluster transfer to client proteins: The [2Fe–2S]-loaded GLRX3 homocomplex donates clusters to the P-loop NTPase scaffold NUBP1, supporting assembly of a [4Fe–4S] on NUBP1 by reductive coupling of two [2Fe–2S] clusters. This transfer is faster and more efficient from the GLRX3 homocomplex than from the GLRX3–BOLA2 complex, which appears more oxidatively stable and a poorer donor to NUBP1 under tested conditions (bargagna2024molecularpathwaysfora pages 128-132, bargagna2024molecularpathwaysfor pages 128-132). Both GLRX3 holo-states can transfer [2Fe–2S] to CIAPIN1/anamorsin, a CIA electron carrier, indicating client- and context-dependent donor behavior (bargagna2024molecularpathwaysfora pages 128-132, bargagna2024molecularpathwaysfor pages 128-132).
- Position relative to ISC/ABCB7/GSH and CIA: In vivo mechanistic mapping shows cytosolic [2Fe–2S] maturation depends on mitochondrial ISC output and ABCB7/Atm1-dependent export, with a role for GSH at or before export, but occurs without CIA components or cGrxs being essential. Conversely, cytosolic/nuclear [4Fe–4S] clients require CIA. This clarifies that GLRX3 is not essential for all [2Fe–2S] delivery in vivo, despite its robust biochemical capacity to bind and transfer [2Fe–2S] in vitro (https://doi.org/10.1073/pnas.2400740121; May 2024) (braymer2024requirementsforthe pages 9-10).
- Mechanistic nuance: Recent synthesis emphasizes that GLRX3–BOLA2 may function as a relatively stable [2Fe–2S] reservoir/chaperone, whereas the GLRX3 homocomplex is a more kinetically competent donor to NUBP1; conditions (redox, reductants, pH) influence the observed transfer efficiencies and remain an active area of investigation (bargagna2024molecularpathwaysfora pages 137-137, bargagna2024molecularpathwaysfora pages 128-132, bargagna2024molecularpathwaysfor pages 128-132).

3) Cellular localization and site of action
- Localization: Experimental studies and reviews place GLRX3 and the GLRX3–BOLA2 complex in the cytosol, participating in cytosolic Fe–S trafficking and in interfacing with CIA components via transfers to CIAPIN1/anamorsin and NUBP1 (bargagna2024molecularpathwaysfora pages 120-124, bargagna2024molecularpathwaysfor pages 120-124, silva2023newperspectiveson pages 9-10). While many Fe–S client enzymes reside in the nucleus, the current 2024 in vivo mapping indicates GLRX3 is not required for general [2Fe–2S] maturation of cytosolic clients and that [4Fe–4S] delivery to nuclear targets is CIA-dependent (PNAS 2024) (braymer2024requirementsforthe pages 9-10).

4) Current understanding of enzymatic/substrate specificity
- Reaction/substrate: GLRX3 is not a classical oxidoreductase in these contexts but a cluster-binding/transfer protein. The relevant “substrates” are [2Fe–2S] clusters (assembled upstream by ISC-derived export) that are bound by GLRX3 (and GLRX3–BOLA2) with GSH acting as a co-ligand; GLRX3 then transfers clusters to cytosolic assembly factors/clients such as NUBP1 and CIAPIN1/anamorsin (bargagna2024molecularpathwaysfora pages 120-124, bargagna2024molecularpathwaysfor pages 120-124, bargagna2024molecularpathwaysfora pages 128-132, bargagna2024molecularpathwaysfor pages 128-132).

5) Expert opinions and mechanistic controversies (2023–2024)
- Essentiality vs. reservoir function: A key 2024 advance shows that cytosolic [2Fe–2S] maturation does not require cGrxs (including GLRX3) in vivo, reframing GLRX3 from an obligatory donor to a context-dependent chaperone/reservoir that can transfer clusters to specific partners under certain conditions (https://doi.org/10.1073/pnas.2400740121; May 2024) (braymer2024requirementsforthe pages 9-10). Complementary biochemical work in 2024 underscores that GLRX3’s different holo-states have distinct stabilities and transfer kinetics, supporting a nuanced, client- and redox-dependent role (bargagna2024molecularpathwaysfora pages 128-132, bargagna2024molecularpathwaysfor pages 128-132).
- Domain architecture consensus: Reviews of CGFS-type Grxs confirm the cytosolic multidomain architecture for GLRX3 and conserved Grx–BOLA physical interactions across kingdoms, supporting the GLRX3–BOLA2 paradigm in humans (Microorganisms 2023; https://doi.org/10.3390/microorganisms11030632; Mar 2023) (silva2023newperspectiveson pages 9-10).

6) Recent developments and latest research (prioritized 2023–2024)
- Structural/biophysical definition of GLRX3 states and transfers: 2024 native MS/IM-MS and spectroscopy define GLRX3 homocomplex vs GLRX3–BOLA2 assemblies and demonstrate differential transfer of [2Fe–2S] to NUBP1, with both states able to deliver to CIAPIN1/anamorsin (bargagna2024molecularpathwaysfora pages 120-124, bargagna2024molecularpathwaysfor pages 120-124, bargagna2024molecularpathwaysfora pages 128-132, bargagna2024molecularpathwaysfor pages 128-132).
- In vivo pathway mapping: 2024 PNAS study delineates the ABCB7/GSH-dependent export feeding [2Fe–2S] maturation independently of CIA and cGrxs, whereas [4Fe–4S] maturation is CIA-dependent; this places GLRX3 as nonessential for bulk [2Fe–2S] biogenesis but compatible with specialized roles (https://doi.org/10.1073/pnas.2400740121; May 2024) (braymer2024requirementsforthe pages 9-10).

7) Disease relevance, applications, and real-world implementations (2023–2024)
- Ewing sarcoma (EwS) dependency and therapeutic stratification (preprint): A 2024 bioRxiv study identifies GLRX3 as an EWSR1::FLI1-dependent vulnerability in EwS. Conditional GLRX3 knockdown reduced proliferation and xenograft growth, increased oxidative stress, and altered iron homeostasis. Drug response profiling suggested GLRX3-high EwS cells are more sensitive to CDK4/6 inhibitors, while GLRX3-low cells are more sensitive to navitoclax (BCL-2/BCL-xL inhibitor) and ferroptosis inducers (erastin). Specific IC50 shifts were reported: palbociclib IC50 increased from 7.9→18.1 µM (A-673) and 3.8→11.3 µM (MHH-ES-1) after GLRX3 knockdown; ribociclib 12.2→41.1 µM (A-673) and 6.7→34.5 µM (MHH-ES-1); navitoclax decreased ~19.5→0.4 µM (A-673) and 8.4→0.3 µM (MHH-ES-1), indicating enhanced sensitivity when GLRX3 is low (bioRxiv; https://doi.org/10.1101/2024.04.24.590877; Apr 2024). These data propose GLRX3 as a predictive biomarker for therapy selection; note status as preprint (vinca2024glutaredoxin3(glrx3) pages 9-12, vinca2024glutaredoxin3(glrx3) pages 3-6, vinca2024glutaredoxin3(glrx3) pages 6-9, vinca2024glutaredoxin3(glrx3) pages 12-16, vinca2024glutaredoxin3(glrx3) pages 1-3).
- Hepatocellular carcinoma (HCC): A 2024 Frontiers in Immunology paper integrates single-cell and spatial transcriptomics with in vitro assays to show GLRX3 is upregulated in HCC, correlates with advanced stage/grade and worse prognosis, and promotes proliferation/invasion via iron metabolism pathways. GLRX3 knockdown reduced proliferation and invasion in vitro (Frontiers in Immunology; https://doi.org/10.3389/fimmu.2024.1496886; Nov 2024) (li2024integratingmultiomicstechniques pages 14-15, li2024integratingmultiomicstechniques pages 21-21).
- AML cuproptosis vulnerability context: A 2024 Science Advances study (cuproptosis via copper ionophore UM4118) found that defects in the Fe–S assembly pathway sensitize AML cells; GLRX3 was among Fe–S-related genes differentially expressed in sensitive vs resistant tiers, linking GLRX3/CIA modules (e.g., MMS19) to vulnerability created by ABCB7 missplicing in SF3B1-mutant AML (Science Advances; https://doi.org/10.1126/sciadv.adl4018; Mar 2024) (bargagna2024molecularpathwaysfora pages 128-132).
- Environmental epigenetics and lung disease: A 2024 Respiratory Research study of COPD patients associated mid-term PM2.5 exposure with DNA methylation changes at GLRX3 among others and discussed GLRX3 as a glutathione-dependent redox buffer increased in lung cancer tissues, linking environmental exposure, redox/iron metabolism, and disease pathways (Respiratory Research; https://doi.org/10.1186/s12931-024-02955-3; Sep 2024) (ji2024theassociationbetween pages 8-9).

8) Relevant statistics and quantitative data
- Biochemical transfer kinetics (qualitative): GLRX3 homocomplex donates [2Fe–2S] to NUBP1 faster and more efficiently than GLRX3–BOLA2 under tested conditions; both donors can metallate CIAPIN1/anamorsin (bargagna2024molecularpathwaysfora pages 128-132, bargagna2024molecularpathwaysfor pages 128-132).
- EwS pharmacology (preprint): IC50 changes with GLRX3 knockdown—palbociclib (A-673 7.9→18.1 µM; MHH-ES-1 3.8→11.3 µM), ribociclib (A-673 12.2→41.1 µM; MHH-ES-1 6.7→34.5 µM), navitoclax (A-673 19.5→0.4 µM; MHH-ES-1 8.4→0.3 µM), and erastin (~4-fold lower IC50s when GLRX3 is low), supporting biomarker-guided strategies (https://doi.org/10.1101/2024.04.24.590877; Apr 2024) (vinca2024glutaredoxin3(glrx3) pages 9-12, vinca2024glutaredoxin3(glrx3) pages 6-9, vinca2024glutaredoxin3(glrx3) pages 12-16).
- EwS dependency datasets (preprint): Dependency score thresholds were cited (e.g., < −0.5 “depletion,” ~−1 pan-essential median) and GLRX3 ranked among EwS-specific dependencies; in vivo xenografts (n=8/group) confirmed growth suppression with inducible GLRX3 knockdown (https://doi.org/10.1101/2024.04.24.590877; Apr 2024) (vinca2024glutaredoxin3(glrx3) pages 26-30, vinca2024glutaredoxin3(glrx3) pages 3-6).

9) Synthesis and pathway model
- Working model: GLRX3 resides in the cytosol as a multidomain CGFS-type glutaredoxin forming: (i) a [2Fe–2S]-bridged GLRX3 homodimer that is an efficient donor to NUBP1 and (ii) a GLRX3–BOLA2 [2Fe–2S] complex that is more stable but a slower donor to NUBP1; both can metallate CIAPIN1/anamorsin. Upstream, mitochondrial ISC output and ABCB7/GSH-dependent export supply the cytosol with the precursor required for [2Fe–2S] maturation; CIA then builds [4Fe–4S] proteins. In vivo, bulk [2Fe–2S] maturation is GLRX3-independent, positioning GLRX3 as a specialized chaperone/reservoir with context-specific roles and disease-relevant consequences when GLRX3 levels shift (braymer2024requirementsforthe pages 9-10, bargagna2024molecularpathwaysfora pages 120-124, bargagna2024molecularpathwaysfor pages 120-124, bargagna2024molecularpathwaysfora pages 128-132, bargagna2024molecularpathwaysfor pages 128-132).

Limitations and open questions
- Essentiality and client scope: PNAS 2024 argues cGrxs are not essential for cytosolic [2Fe–2S] maturation, but biochemical data show robust GLRX3 transfer in vitro; reconciling in vivo nonessentiality with specialized client delivery (e.g., NUBP1 vs CIAPIN1) and redox-state dependence remains an open focus (braymer2024requirementsforthe pages 9-10, bargagna2024molecularpathwaysfora pages 128-132, bargagna2024molecularpathwaysfor pages 128-132).
- Nuclear delivery: Many final nuclear client proteins are [4Fe–4S] and CIA-dependent; direct roles for GLRX3 in nuclear delivery remain to be clarified under physiological conditions in human cells (braymer2024requirementsforthe pages 9-10).

References (URLs and publication dates)
- Braymer JJ et al. Requirements for the biogenesis of [2Fe–2S] proteins in the human and yeast cytosol. PNAS. Published May 2024. URL: https://doi.org/10.1073/pnas.2400740121 (braymer2024requirementsforthe pages 9-10).
- Bargagna B. Molecular pathways for the maturation of mitochondrial and cytosolic human Fe–S proteins. 2024. Excerpts report GLRX3–BOLA2 and GLRX3 homocomplex states, transfers to NUBP1 and CIAPIN1; multiple pages cited above (bargagna2024molecularpathwaysfora pages 137-137, bargagna2024molecularpathwaysfora pages 120-124, bargagna2024molecularpathwaysfor pages 120-124, bargagna2024molecularpathwaysfora pages 128-132, bargagna2024molecularpathwaysfor pages 128-132).
- da Silva AA et al. New Perspectives on BolA. Microorganisms. Published Mar 2023. URL: https://doi.org/10.3390/microorganisms11030632 (silva2023newperspectiveson pages 9-10).
- Vinca E et al. Glutaredoxin 3 (GLRX3) confers a fusion oncogene-dependent vulnerability to Ewing sarcoma. bioRxiv preprint. Posted Apr 2024. URL: https://doi.org/10.1101/2024.04.24.590877 (vinca2024glutaredoxin3(glrx3) pages 26-30, vinca2024glutaredoxin3(glrx3) pages 9-12, vinca2024glutaredoxin3(glrx3) pages 3-6, vinca2024glutaredoxin3(glrx3) pages 6-9, vinca2024glutaredoxin3(glrx3) pages 12-16, vinca2024glutaredoxin3(glrx3) pages 1-3).
- Li Y et al. GLRX3 regulates the immune microenvironment and promotes hepatocellular carcinoma via iron metabolism pathways. Frontiers in Immunology. Published Nov 2024. URL: https://doi.org/10.3389/fimmu.2024.1496886 (li2024integratingmultiomicstechniques pages 14-15, li2024integratingmultiomicstechniques pages 21-21).
- Moison C et al. SF3B1 mutations provide genetic vulnerability to copper ionophores in AML. Science Advances. Published Mar 2024. URL: https://doi.org/10.1126/sciadv.adl4018 (bargagna2024molecularpathwaysfora pages 128-132).
- Ji HW et al. PM2.5 exposure and DNA methylation among COPD patients. Respiratory Research. Published Sep 2024. URL: https://doi.org/10.1186/s12931-024-02955-3 (ji2024theassociationbetween pages 8-9).

References

1. (bargagna2024molecularpathwaysfora pages 120-124): B Bargagna. Molecular pathways for the maturation of mitochondrial and cytosolic human fe-s proteins. Unknown journal, 2024.

2. (bargagna2024molecularpathwaysfor pages 120-124): B Bargagna. Molecular pathways for the maturation of mitochondrial and cytosolic human fe-s proteins. Unknown journal, 2024.

3. (silva2023newperspectiveson pages 9-10): Ana Alves da Silva, Lisete Galego, and Cecília Maria Arraiano. New perspectives on bola: a still mysterious protein connecting morphogenesis, biofilm production, virulence, iron metabolism, and stress survival. Microorganisms, 11:632, Mar 2023. URL: https://doi.org/10.3390/microorganisms11030632, doi:10.3390/microorganisms11030632. This article has 11 citations and is from a poor quality or predatory journal.

4. (bargagna2024molecularpathwaysfora pages 128-132): B Bargagna. Molecular pathways for the maturation of mitochondrial and cytosolic human fe-s proteins. Unknown journal, 2024.

5. (braymer2024requirementsforthe pages 9-10): Joseph J. Braymer, Oliver Stehling, Martin Stümpfig, Ralf Rösser, Farah Spantgar, Catharina M. Blinn, Ulrich Mühlenhoff, Antonio J. Pierik, and Roland Lill. Requirements for the biogenesis of [2fe-2s] proteins in the human and yeast cytosol. Proceedings of the National Academy of Sciences, May 2024. URL: https://doi.org/10.1073/pnas.2400740121, doi:10.1073/pnas.2400740121. This article has 14 citations and is from a highest quality peer-reviewed journal.

6. (bargagna2024molecularpathwaysfor pages 128-132): B Bargagna. Molecular pathways for the maturation of mitochondrial and cytosolic human fe-s proteins. Unknown journal, 2024.

7. (bargagna2024molecularpathwaysfora pages 137-137): B Bargagna. Molecular pathways for the maturation of mitochondrial and cytosolic human fe-s proteins. Unknown journal, 2024.

8. (vinca2024glutaredoxin3(glrx3) pages 9-12): Endrit Vinca, Anna C. Ehlers, Alina Ritter, David Obermeier, Cornelius M. Funk, Florian H. Geyer, Melissa Schmucker, Jing Li, Malenka Zimmermann, A. Katharina Ceranski, Fabia Fuchslocher, Christina Mertens, Ruiyue Qiu, Martina M. Muckenthaler, Alina Dahlhaus, Silvia von Karstedt, Roland Imle, Ana Banito, Javier Alonso, Heike Peterziel, Olaf Witt, Ina Oehme, Florencia Cidre-Aranaz, Thomas G. P. Grünewald, and Shunya Ohmura. Glutaredoxin 3 (glrx3) confers a fusion oncogene-dependent vulnerability to ewing sarcoma. bioRxiv, Apr 2024. URL: https://doi.org/10.1101/2024.04.24.590877, doi:10.1101/2024.04.24.590877. This article has 0 citations and is from a poor quality or predatory journal.

9. (vinca2024glutaredoxin3(glrx3) pages 3-6): Endrit Vinca, Anna C. Ehlers, Alina Ritter, David Obermeier, Cornelius M. Funk, Florian H. Geyer, Melissa Schmucker, Jing Li, Malenka Zimmermann, A. Katharina Ceranski, Fabia Fuchslocher, Christina Mertens, Ruiyue Qiu, Martina M. Muckenthaler, Alina Dahlhaus, Silvia von Karstedt, Roland Imle, Ana Banito, Javier Alonso, Heike Peterziel, Olaf Witt, Ina Oehme, Florencia Cidre-Aranaz, Thomas G. P. Grünewald, and Shunya Ohmura. Glutaredoxin 3 (glrx3) confers a fusion oncogene-dependent vulnerability to ewing sarcoma. bioRxiv, Apr 2024. URL: https://doi.org/10.1101/2024.04.24.590877, doi:10.1101/2024.04.24.590877. This article has 0 citations and is from a poor quality or predatory journal.

10. (vinca2024glutaredoxin3(glrx3) pages 6-9): Endrit Vinca, Anna C. Ehlers, Alina Ritter, David Obermeier, Cornelius M. Funk, Florian H. Geyer, Melissa Schmucker, Jing Li, Malenka Zimmermann, A. Katharina Ceranski, Fabia Fuchslocher, Christina Mertens, Ruiyue Qiu, Martina M. Muckenthaler, Alina Dahlhaus, Silvia von Karstedt, Roland Imle, Ana Banito, Javier Alonso, Heike Peterziel, Olaf Witt, Ina Oehme, Florencia Cidre-Aranaz, Thomas G. P. Grünewald, and Shunya Ohmura. Glutaredoxin 3 (glrx3) confers a fusion oncogene-dependent vulnerability to ewing sarcoma. bioRxiv, Apr 2024. URL: https://doi.org/10.1101/2024.04.24.590877, doi:10.1101/2024.04.24.590877. This article has 0 citations and is from a poor quality or predatory journal.

11. (vinca2024glutaredoxin3(glrx3) pages 12-16): Endrit Vinca, Anna C. Ehlers, Alina Ritter, David Obermeier, Cornelius M. Funk, Florian H. Geyer, Melissa Schmucker, Jing Li, Malenka Zimmermann, A. Katharina Ceranski, Fabia Fuchslocher, Christina Mertens, Ruiyue Qiu, Martina M. Muckenthaler, Alina Dahlhaus, Silvia von Karstedt, Roland Imle, Ana Banito, Javier Alonso, Heike Peterziel, Olaf Witt, Ina Oehme, Florencia Cidre-Aranaz, Thomas G. P. Grünewald, and Shunya Ohmura. Glutaredoxin 3 (glrx3) confers a fusion oncogene-dependent vulnerability to ewing sarcoma. bioRxiv, Apr 2024. URL: https://doi.org/10.1101/2024.04.24.590877, doi:10.1101/2024.04.24.590877. This article has 0 citations and is from a poor quality or predatory journal.

12. (vinca2024glutaredoxin3(glrx3) pages 1-3): Endrit Vinca, Anna C. Ehlers, Alina Ritter, David Obermeier, Cornelius M. Funk, Florian H. Geyer, Melissa Schmucker, Jing Li, Malenka Zimmermann, A. Katharina Ceranski, Fabia Fuchslocher, Christina Mertens, Ruiyue Qiu, Martina M. Muckenthaler, Alina Dahlhaus, Silvia von Karstedt, Roland Imle, Ana Banito, Javier Alonso, Heike Peterziel, Olaf Witt, Ina Oehme, Florencia Cidre-Aranaz, Thomas G. P. Grünewald, and Shunya Ohmura. Glutaredoxin 3 (glrx3) confers a fusion oncogene-dependent vulnerability to ewing sarcoma. bioRxiv, Apr 2024. URL: https://doi.org/10.1101/2024.04.24.590877, doi:10.1101/2024.04.24.590877. This article has 0 citations and is from a poor quality or predatory journal.

13. (li2024integratingmultiomicstechniques pages 14-15): Yang Li, Yuan Chen, Yang Zhang, Yunsheng Fang, Ling Wu, Ying Zhao, Danqiong Wang, and Xiaoyuan Qiao. Integrating multi-omics techniques and in vitro experiments reveals that glrx3 regulates the immune microenvironment and promotes hepatocellular carcinoma cell proliferation and invasion through iron metabolism pathways. Frontiers in Immunology, Nov 2024. URL: https://doi.org/10.3389/fimmu.2024.1496886, doi:10.3389/fimmu.2024.1496886. This article has 3 citations and is from a peer-reviewed journal.

14. (li2024integratingmultiomicstechniques pages 21-21): Yang Li, Yuan Chen, Yang Zhang, Yunsheng Fang, Ling Wu, Ying Zhao, Danqiong Wang, and Xiaoyuan Qiao. Integrating multi-omics techniques and in vitro experiments reveals that glrx3 regulates the immune microenvironment and promotes hepatocellular carcinoma cell proliferation and invasion through iron metabolism pathways. Frontiers in Immunology, Nov 2024. URL: https://doi.org/10.3389/fimmu.2024.1496886, doi:10.3389/fimmu.2024.1496886. This article has 3 citations and is from a peer-reviewed journal.

15. (ji2024theassociationbetween pages 8-9): Hyun Woo Ji, Jieun Kang, Hwan-Cheol Kim, Junghee Jung, Seon-Jin Lee, Ji Ye Jung, and Sei Won Lee. The association between cumulative exposure to pm2.5 and dna methylation measured using methyl-capture sequencing among copd patients. Respiratory Research, Sep 2024. URL: https://doi.org/10.1186/s12931-024-02955-3, doi:10.1186/s12931-024-02955-3. This article has 3 citations and is from a domain leading peer-reviewed journal.

16. (vinca2024glutaredoxin3(glrx3) pages 26-30): Endrit Vinca, Anna C. Ehlers, Alina Ritter, David Obermeier, Cornelius M. Funk, Florian H. Geyer, Melissa Schmucker, Jing Li, Malenka Zimmermann, A. Katharina Ceranski, Fabia Fuchslocher, Christina Mertens, Ruiyue Qiu, Martina M. Muckenthaler, Alina Dahlhaus, Silvia von Karstedt, Roland Imle, Ana Banito, Javier Alonso, Heike Peterziel, Olaf Witt, Ina Oehme, Florencia Cidre-Aranaz, Thomas G. P. Grünewald, and Shunya Ohmura. Glutaredoxin 3 (glrx3) confers a fusion oncogene-dependent vulnerability to ewing sarcoma. bioRxiv, Apr 2024. URL: https://doi.org/10.1101/2024.04.24.590877, doi:10.1101/2024.04.24.590877. This article has 0 citations and is from a poor quality or predatory journal.

Citations

1. braymer2024requirementsforthe pages 9-10
2. silva2023newperspectiveson pages 9-10
3. bargagna2024molecularpathwaysfora pages 128-132
4. ji2024theassociationbetween pages 8-9
5. bargagna2024molecularpathwaysfora pages 120-124
6. bargagna2024molecularpathwaysfor pages 120-124
7. bargagna2024molecularpathwaysfor pages 128-132
8. bargagna2024molecularpathwaysfora pages 137-137
9. li2024integratingmultiomicstechniques pages 14-15
10. li2024integratingmultiomicstechniques pages 21-21
11. 2Fe–2S
12. 4Fe–4S
13. 2fe-2s
14. https://doi.org/10.1073/pnas.2400740121;
15. https://doi.org/10.3390/microorganisms11030632;
16. https://doi.org/10.1101/2024.04.24.590877;
17. https://doi.org/10.3389/fimmu.2024.1496886;
18. https://doi.org/10.1126/sciadv.adl4018;
19. https://doi.org/10.1186/s12931-024-02955-3;
20. https://doi.org/10.1073/pnas.2400740121
21. https://doi.org/10.3390/microorganisms11030632
22. https://doi.org/10.1101/2024.04.24.590877
23. https://doi.org/10.3389/fimmu.2024.1496886
24. https://doi.org/10.1126/sciadv.adl4018
25. https://doi.org/10.1186/s12931-024-02955-3
26. https://doi.org/10.3390/microorganisms11030632,
27. https://doi.org/10.1073/pnas.2400740121,
28. https://doi.org/10.1101/2024.04.24.590877,
29. https://doi.org/10.3389/fimmu.2024.1496886,
30. https://doi.org/10.1186/s12931-024-02955-3,

Glutaredoxin-3 (GLRX3): A Comprehensive Analysis of Structure, Function, and Biological Role in Iron-Sulfur Cluster Biogenesis and Cellular Homeostasis

The human glutaredoxin-3 (GLRX3), also known as protein kinase C-interacting cousin of thioredoxin (PICOT), represents a multifunctional protein with emerging significance in cellular iron metabolism, redox homeostasis, and DNA damage response mechanisms. Encoded by the GLRX3 gene located on chromosome 10 and designated with UniProt accession O76003, this ubiquitously distributed protein has evolved as a critical regulator of iron-sulfur cluster assembly and distribution within the cytoplasm and nucleus of mammalian cells[3][4][40]. Since its discovery in the year 2000 as a binding partner for protein kinase C-theta (PKCθ), GLRX3 has emerged from relative obscurity to become recognized as an essential factor for embryonic development, cellular stress adaptation, and prevention of age-related decline[5][45][51]. This comprehensive analysis examines the molecular architecture, biochemical mechanisms, cellular localization dynamics, and pathophysiological roles of GLRX3, integrating evidence from structural studies, molecular genetics, and functional investigations that collectively establish this protein as a central hub in iron metabolism and cellular survival pathways.

Structural Architecture and Multidomain Organization

GLRX3 exhibits a distinctive three-domain architecture that fundamentally distinguishes it from classical thioredoxins and glutaredoxins, endowing the protein with unique mechanistic capabilities for iron-sulfur cluster handling[3][19][55]. The protein comprises an N-terminal thioredoxin (Trx) homology domain and two tandem C-terminal monothiol glutaredoxin (Grx) homology domains, each containing the characteristic CGFS (cysteine-glycine-phenylalanine-serine) motif that defines class II glutaredoxins[5][19][55]. This structural configuration represents an evolutionary adaptation distinct from single-domain glutaredoxins or thioredoxins found in simpler organisms, reflecting the increased complexity of iron metabolism in higher eukaryotes[25]. Notably, despite possessing an N-terminal region with homology to thioredoxin domains, the critical catalytic motif essential for classical thioredoxin oxidoreductase activity is absent, meaning GLRX3 lacks conventional thioredoxin catalytic function[3][40]. Rather, this domain appears to serve scaffolding or regulatory purposes, as demonstrated through targeted mutagenesis studies where researchers have identified that the Trx-like domain participates in substrate binding and interacting partner recognition[19][21].

The two C-terminal Grx domains constitute the functionally active regions for iron-sulfur cluster coordination and represent the primary structural determinants of GLRX3's biological role[7][33][55]. Each Grx domain possesses a CGFS active site motif where the conserved cysteine residue serves as a critical ligand for iron-sulfur cluster coordination[3][7][14]. Structurally, these domains enable the formation of homodimeric complexes wherein two GLRX3 molecules bridge iron-sulfur clusters between their interface, a configuration stabilized through coordinated binding of the cluster's iron and sulfide atoms to the cysteine residues of each monomer as well as to molecules of reduced glutathione (GSH) that serve as essential cofactors[7][10][17][33]. The glutathione molecules coordinate the cluster through their thiol and amino groups, creating a quaternary complex wherein iron-sulfur cluster ligation depends simultaneously on protein cysteine residues, glutathione cofactors, and the metal-sulfide core structure[7][25][33][42]. This structural interdependence of protein, cofactor, and metal cluster represents a fundamentally different architecture compared to classical iron-sulfur cluster proteins where the cluster directly ligates to protein cysteine residues alone[25].

Sequence homology analyses reveal that the Grx domains of human GLRX3 share approximately 40-50% sequence identity with the corresponding domains of yeast Grx3 and Grx4 proteins, indicating substantial evolutionary conservation despite divergence in organismal complexity[2][9]. However, the identity between the Trx domains is considerably lower, at less than 27%, suggesting differential selective pressures for preserving these distinct functional modules[2][9]. Alternative splicing of the GLRX3 transcript can generate variant proteins, and pseudogenes of this locus are present on chromosomes 6 and 9, though these pseudogenic sequences do not produce functional proteins[3][40]. The remarkable conservation of the Grx domains across vast evolutionary distances, from fungi to higher mammals, underscores the fundamental importance of the iron-sulfur cluster chaperoning function throughout eukaryotic biology[2][9][30].

Iron-Sulfur Cluster Biology and Chaperoning Mechanisms

The primary biochemical function of GLRX3 centers on its capacity to coordinate, transport, and deliver iron-sulfur clusters to target apoproteins, a function that positions this protein at the interface between mitochondrial iron-sulfur cluster synthesis and cytoplasmic protein maturation[7][8][20][30]. Human GLRX3 specifically functions as a [2Fe-2S] cluster chaperone, capable of binding two iron atoms coordinated with two sulfide atoms through interactions with glutathione, cysteine residues within the CGFS motifs, and histidine residues from partner proteins[7][10][20][33]. The biochemical mechanism of cluster transfer has been elucidated through multiple independent studies utilizing spectroscopic approaches, protein chemistry, and cell-based investigations that collectively demonstrate a directional flux of iron-sulfur clusters from GLRX3 to target proteins requiring these essential prosthetic groups[7][10][20][30].

In molecular detail, dimeric cluster-bridged GLRX3 molecules—wherein each GLRX3 monomer coordinates half of a [2Fe-2S] cluster through its CGFS active site—transfer their bound clusters to protein targets essential for cytosolic iron-sulfur protein assembly (CIA) machinery[7][20][33][42][50]. The transfer of [2Fe-2S] clusters from GLRX3 to target proteins such as NUBP1, a P-loop NTPase critical for early-stage CIA processing, occurs through direct protein-protein interaction wherein the cluster remains protein-bound throughout the transfer process, ensuring no loss of this extremely labile prosthetic group in solution[7][20][33][50]. Remarkably, the incoming [2Fe-2S] clusters can undergo reductive coupling in the presence of glutathione to form [4Fe-4S] clusters on bifunctional target proteins that possess dual cluster-binding sites[7][20][33][42]. This reductive coupling mechanism represents a sophisticated biochemical achievement wherein GLRX3 essentially functions as a nucleation point enabling the synthesis of higher-order iron-sulfur clusters through controlled reduction by glutathione, which acts as the biological reductant in this process[7][33]. The [4Fe-4S] clusters assembled on N-terminal cluster-binding motifs exhibit tight binding and stability, while those assembled on C-terminal motifs display labile characteristics, providing a potential regulatory mechanism for cluster dynamics within the cell[7][20][33].

The in vivo assembly efficiency of iron-sulfur clusters via GLRX3-mediated transfer achieves approximately 60% efficiency under physiological conditions, indicating that while GLRX3 represents an important pathway for cluster biogenesis, additional redundant or complementary mechanisms exist for cluster maturation[7]. However, GLRX3 knockout or severe depletion studies reveal that this protein is particularly critical for maturation of specific iron-sulfur protein substrates, most notably cytosolic [4Fe-4S]-cluster-containing proteins required for DNA repair, metabolic functions, and other essential cellular processes[41][49]. Surprisingly, GLRX3 does not appear essential for cytosolic [2Fe-2S]-cluster protein assembly, suggesting functional redundancy or alternative pathway sufficiency for this simpler cluster form[41][49]. GLRX3 specifically collaborates with the BolA2 protein to form [2Fe-2S]-cluster-bridged heterocomplexes in human cells, representing a heterocomplex that responds dynamically to cellular iron availability and serves as a rapidly expandable pool of iron-sulfur clusters[10][17][30]. Cellular GLRX3-BolA2 complexes increase 6-8 fold in response to elevated iron supplementation and decrease accordingly under iron-depleted conditions, establishing these complexes as iron-responsive storage and distribution centers[10][17].

The interaction between GLRX3 and BolA2 displays remarkable iron-responsiveness, increasing within one hour of iron supplementation and reaching maximum levels by four hours, indicating a rapid and sensitive mechanism for responding to changes in cellular iron status[10][17]. Unlike yeast GLRX3 orthologs, human GLRX3-BolA2 complex formation strictly requires coordination of iron-sulfur clusters, as cluster-free GLRX3 and BolA2 apo-proteins do not stably associate in mammalian cells, representing a mechanistic difference from simpler organisms[10][17]. The functional significance of this iron-dependent interaction lies in its capacity to deliver [2Fe-2S] clusters to downstream recipients within the CIA pathway, including anamorsin (CIAPIN1), a [2Fe-2S]-cluster-containing protein functioning early in the cytosolic assembly process[10][17][30][52]. This hierarchical organization of iron-sulfur cluster distribution, wherein mitochondrial synthesis is followed by GLRX3-BolA2 mediated cytosolic delivery and subsequent transfer to downstream assembly scaffolds, represents an elegant solution to the challenge of safely managing these highly labile and potentially toxic metal-sulfide clusters within the reducing environment of the cytoplasm[7][10][30][41].

Cellular Localization and Subcellular Dynamics

GLRX3 demonstrates a remarkable capacity for dynamic subcellular redistribution in response to cellular stress conditions, representing a sophisticated regulatory mechanism for concentrating this protein at sites requiring enhanced iron-sulfur cluster availability or antioxidant protection[25][27]. Under normal growth conditions, GLRX3 is predominantly localized to the cytoplasm in a relatively diffuse distribution pattern, as demonstrated through fluorescence microscopy of GLRX3-RFP fusion proteins and biochemical fractionation studies of transfected mammalian cells[27]. However, upon exposure to oxidative stress induced by hydrogen peroxide or other radical-generating agents, GLRX3 undergoes a reversible and redox-dependent translocation into the nucleus, accumulating there in response to the perceived oxidative insult[27]. This nuclear accumulation is reversible in a temporally-dependent fashion, with GLRX3 returning to predominantly cytoplasmic localization as cellular redox conditions normalize, indicating an active sensing and response mechanism rather than irreversible sequestration[27]. The mechanism of nuclear translocation does not depend upon the N-terminal Trx-like domain nor upon the catalytic cysteine residues within the CGFS motifs, suggesting a redox-sensing mechanism distinct from the cluster-coordinating function and potentially involving other cysteine residues or sensing domains[27].

The biological significance of stress-induced nuclear translocation relates to GLRX3's emerging role in nuclear functions including DNA damage response and epigenetic regulation[27][45][51]. Overexpression of GLRX3 targeted to the nucleus through artificial targeting sequences is sufficient to suppress cellular sensitivity to oxidative stress and reduce reactive oxygen species production, establishing a direct relationship between nuclear GLRX3 localization and cellular protection against oxidative injury[27]. Furthermore, GLRX3 displays partial localization at γH2AX-containing foci, the sites of DNA double-strand breaks, under genotoxic conditions, suggesting direct involvement in DNA damage response signaling at the site of DNA injury[45][51]. Additionally, GLRX3 has been found to localize to chromatin-associated regions where it interacts with the embryonic ectoderm development (EED) protein, a core component of Polycomb repressive complex 2 (PRC2), suggesting a role in regulating chromatin structure and epigenetic gene silencing[5][32][35].

The interaction between GLRX3 and EED occurs through each of GLRX3's two C-terminal Grx homology domains, establishing a bivalent interaction interface that modulates PRC2-mediated histone trimethylation at specific genomic loci[5][32][35]. GLRX3 binding to chromatin-associated EED reduces the occupancy of PRC2 complex components at select target genes, particularly affecting H3K27me3 levels at the CCND2 gene promoter encoding cyclin D2[5][32][35]. This GLRX3-dependent modulation of PRC2 activity results in increased CCND2 transcription, linking GLRX3 to cell cycle progression through an epigenetic mechanism[5][32][35]. The discovery that GLRX3 can modify PRC2-mediated transcriptional silencing introduces an unexpected connection between iron metabolism, cellular redox status, and epigenetic gene regulation, suggesting that GLRX3 may coordinate multiple layers of cellular regulation responding to iron availability and oxidative stress[5][32][35]. These findings propose a sophisticated regulatory architecture wherein GLRX3 integrates metabolic signals (iron status) with epigenetic modifications that control cell proliferation, potentially explaining some of the oncogenic associations of GLRX3 dysregulation in cancer cells[5][32][35].

Iron Metabolism and Cellular Homeostatic Regulation

GLRX3 functions as a critical regulator of cellular iron homeostasis through multiple interconnected mechanisms that collectively ensure appropriate iron acquisition, utilization, and storage according to cellular needs[8][11][30]. The depletion of GLRX3 expression in cultured mammalian cells results in activation of iron-regulatory protein 1 (IRP1), a key component of the iron-sensing system that post-transcriptionally regulates iron metabolism genes[8][11][24]. Under normal iron-replete conditions, IRP1 exists as an iron-sulfur cluster-containing protein that functions as aconitase and does not bind to iron-responsive elements (IREs) in mRNA. However, GLRX3-depleted cells display markedly reduced IRP1 protein levels and activity, indicating failed maturation of the iron-sulfur cluster required for aconitase function[8][11][24]. Consequently, IRP1 adopts its apoprotein form lacking iron-sulfur clusters, converting it into an active IRE-binding protein that suppresses translation of transferrin receptor mRNA (which promotes iron uptake) and enhances translation of ferritin mRNA (which stores iron)[8][11][24][30].

This paradoxical situation in GLRX3-deficient cells—wherein the cellular system perceives iron starvation despite normal or elevated intracellular iron levels—reveals GLRX3's central position in iron sensing[8][11][30]. GLRX3-depleted cells accumulate increased cellular iron content but cannot appropriately utilize this iron for biosynthetic purposes, as the deficiency of iron-sulfur cluster-containing proteins limits the cell's capacity to synthesize essential iron-dependent enzymes[8][11][30]. The consequences manifest as activation of the integrated stress response (ISR) pathway through the kinase GCN2, which senses the cellular inability to efficiently use iron through Aft1/Aft2 transcriptional activation[2][9][14][38][39]. Multiple iron-consuming pathways become simultaneously impaired in GLRX3-deficient cells, including hemoglobin maturation during erythropoiesis, ribonucleotide reductase activity required for DNA synthesis, and other iron-sulfur cluster-dependent processes throughout metabolism[8][11][24][30].

The in vivo significance of GLRX3 for iron metabolism was established through studies in zebrafish embryos, wherein GLRX3 depletion during embryogenesis severely impairs hemoglobin maturation, the major iron-consuming process during erythroid development[8][11]. The developmental dependence upon GLRX3 is underscored by the embryonic lethality of homozygous GLRX3 knockout mice, occurring between embryonic day 12.5 and 14.5 during a period of intense erythropoiesis and general tissue growth[26][29]. These developmental studies establish GLRX3 as essential for embryonic viability, placing it among the most critical iron metabolism factors for mammalian development[26][29].

GLRX3 also collaborates with GMP synthase in a novel pathway connecting iron metabolism to guanine nucleotide biosynthesis and cellular stress responses[2][9][14][38][43][46]. The interaction between GLRX3 and GMP synthase occurs through iron-sulfur cluster-bridged complexes, demonstrating dependence upon cluster coordination for complex formation[2][9][14][38][43][46]. When cellular iron becomes depleted, this GLRX3-GMP synthase interaction is disrupted, leading to altered GMP/GTP synthesis and activation of GCN2 stress response pathway[2][9][14][38][43][46]. This mechanistic connection suggests that iron availability is coupled to the cellular balance of purines and stress responses, creating an integrated metabolic checkpoint that restricts protein synthesis when iron becomes limiting[2][9][14][38][43][46]. The evolutionary conservation of this GLRX3-GMP synthase interaction from yeast to humans, despite divergent metabolic architectures between these organisms, underscores the fundamental importance of coupling iron sensing to stress response and biosynthetic regulation[2][9][14][38][43][46].

Protein-Protein Interactions and Signaling Pathways

GLRX3 participates in an expanding network of protein-protein interactions that mediate its diverse cellular functions and link iron metabolism to multiple signaling cascades[3][5][6][45][51]. The original discovery of GLRX3 identified its interaction with protein kinase C-theta (PKCθ), and subsequent studies have established that GLRX3 binds to the regulatory domain of PKCθ and modulates its activity and subcellular localization[3][5][6]. Upon activation of T cells through antigen receptor engagement, GLRX3 and PKCθ translocate together to the plasma membrane region extending into the immunological synapse, suggesting a role for GLRX3 in T cell signal transduction[6][48]. Beyond the PKCθ interaction, GLRX3 engages with multiple metabolic and regulatory proteins through iron-sulfur cluster-dependent mechanisms, including IRP1 (iron-regulatory protein 1) through facilitation of [4Fe-4S] cluster assembly[8][11][24], BolA2 through formation of [2Fe-2S]-cluster-bridged complexes that serve as iron-responsive chaperone pairs[10][17][30], and EED (embryonic ectoderm development) through direct protein-protein interaction at chromatin sites[5][32][35].

The interaction between GLRX3 and NUBP1 (nucleotide-binding protein 1), a P-loop NTPase essential for early-stage CIA machinery function, represents a particularly well-characterized mechanistic interaction wherein GLRX3 directly transfers its [2Fe-2S] clusters to NUBP1 to facilitate the assembly of dual [4Fe-4S] clusters on this downstream target protein[7][20][33][42][50][52]. This transfer is bidirectional in terms of cluster oxidation-reduction state, with GLRX3 acting as a reductant that facilitates the conversion of incoming [2Fe-2S] clusters into [4Fe-4S] clusters through coupled reduction mechanisms[7][20][33][42][52]. GLRX3 also participates in iron-sensing mechanisms through its capacity to interact with the transcriptional factors Aft1 and Aft2 in yeast models, with orthologous functions likely conserved in mammals, wherein the iron-sulfur cluster bound to GLRX3 serves as a direct sensor of intracellular iron status[2][9][14][30][38][39][43].

Beyond iron-sulfur cluster-mediated interactions, GLRX3 participates in DNA damage response pathways through mechanisms requiring its nuclear localization[45][51]. Upon genotoxic stress induced by etoposide or camptothecin, GLRX3 facilitates phosphorylation of ATR (ataxia telangiectasia and Rad3-related) protein kinase, which serves as a master regulator of the DNA damage checkpoint response[45][51]. GLRX3-deficient cells show markedly reduced and delayed phosphorylation of ATR, Chk1, and Chk2 kinases in response to genotoxic drugs, as well as diminished phosphorylation of the histone variant H2AX (γH2AX) at DNA double-strand break sites[45][51]. These deficiencies result in increased caspase-3 activation and reduced survival of GLRX3-deficient cells exposed to DNA-damaging agents[45][51]. Interestingly, the effect of GLRX3 on drug-induced H2AX phosphorylation is independent of the cellular reactive oxygen species levels, indicating a direct role in DNA damage signaling rather than merely an antioxidant function[45][51]. The mechanism likely involves GLRX3's capacity to support the redox environment required for ATR kinase activation or to directly facilitate ATR recruitment to sites of DNA damage[45][51].

Disease Associations and Cancer-Related Dysregulation

GLRX3 expression is frequently dysregulated in multiple human malignancies, with overexpression associated with aggressive disease phenotypes and poor clinical outcomes, positioning this protein as an emerging oncogenic factor with therapeutic potential[15][31][34]. In hepatocellular carcinoma (HCC), GLRX3 overexpression correlates with enhanced tumor cell proliferation, invasion, and immune evasion through mechanisms involving both direct iron metabolism dysregulation and activation of pro-survival signaling pathways[34]. Survival analysis in HCC cohorts demonstrates that patients with elevated GLRX3 expression exhibit significantly shortened overall survival and progression-free survival compared to those with low GLRX3 levels, establishing GLRX3 as a prognostic marker for poor outcomes[34]. The mechanism by which GLRX3 promotes HCC progression involves dysregulated iron metabolism affecting immune cell function within the tumor microenvironment, as GLRX3-mediated iron metabolism alterations diminish the cytotoxic capacity of T cells and reduce their ability to eliminate tumor cells[34].

In nasopharyngeal carcinoma (NPC), GLRX3 knockdown experiments demonstrate substantial inhibition of cell proliferation in vitro and tumorigenesis in vivo, alongside suppression of cancer cell migration and invasion through reversal of epithelial-mesenchymal transition (EMT)[31]. Mechanistically, GLRX3 maintains reduced reactive oxygen species (ROS) levels through its antioxidant functions, thereby promoting NPC cell survival and allowing the maintenance of virus latency for Epstein-Barr virus (EBV), which is intimately associated with NPC development and persistence[31]. GLRX3 stabilization correlates positively with epidermal growth factor receptor (EGFR) expression and negatively with ROS generation, establishing a signaling axis wherein GLRX3 suppresses oxidative stress to activate the EGFR/Akt pathway supporting cancer cell survival and proliferation[31]. Furthermore, GLRX3 knockdown in NPC cells significantly downregulates EGFR expression at both mRNA and protein levels, indicating that GLRX3 loss prevents EGF-mediated Akt phosphorylation and reduces cancer cell proliferation capacity[31].

Lung cancer cells also display GLRX3 overexpression, and knockdown studies in lung cancer cell lines reveal substantial reduction of proliferation and colony formation capability, accompanied by enhanced apoptosis through increased caspase-3 activity[15]. These observations consistently indicate that GLRX3 functions as a survival factor for multiple cancer types through coupled mechanisms of antioxidant defense and metabolic optimization. Notably, GLRX3 expression frequently serves as a marker correlating with cancer progression in breast cancer, hepatocellular carcinoma, and lung cancer, suggesting a general principle whereby enhanced GLRX3 expression supports the transformed phenotype through multiple mechanisms[31].

The molecular basis of GLRX3's oncogenic properties relates both to its core iron metabolism functions and to its emerging regulatory roles in epigenetics and DNA damage signaling. Enhanced GLRX3 levels facilitate increased iron-sulfur cluster synthesis supporting enhanced biosynthetic capacity required for tumor growth, while simultaneously suppressing ROS-mediated damage that would otherwise limit malignant transformation[31][34]. Additionally, GLRX3's interaction with the PRC2 complex enables altered epigenetic silencing patterns that may promote cancer-associated gene expression programs[5][32][35]. The DNA damage response defects consequent to GLRX3 depletion might paradoxically be expected to promote genome instability and cancer development, yet cancer cells typically upregulate GLRX3, suggesting that cancer cells benefit from enhanced DNA damage tolerance mechanisms including GLRX3-mediated ATR pathway support[45][51].

Beyond cancer, GLRX3 variants have been identified in association with X-linked intellectual disability with short stature and obesity syndrome and with multiple mitochondrial dysfunctions syndrome, linking GLRX3 dysfunction to severe developmental abnormalities[3][40]. The discovery that homozygous GLRX3 inactivation causes embryonic lethality in mice between days 12.5-14.5 underscores the absolute requirement for this protein during critical developmental windows[26][29].

Evolutionary Conservation and Mechanistic Insights from Model Organisms

The evolutionary conservation of GLRX3 and its yeast orthologs Grx3 and Grx4 from single-celled fungi to complex multicellular mammals reflects the fundamental importance of this protein family for eukaryotic iron metabolism[2][9][30][43][46]. Despite sequence divergence and some mechanistic differences between yeast and mammalian systems, the core function of monothiol glutaredoxins as iron-sulfur cluster chaperones operating through iron-sulfur cluster-dependent interactions with metabolic proteins and transcription factors has been conserved across hundreds of millions of years of evolution[2][9][30][43][46][59]. Yeast genetic studies have proven particularly valuable for elucidating GLRX3 mechanisms, as the simpler architecture and better-characterized metabolic dependencies of unicellular organisms enable identification of functional interactions that might remain obscured in mammalian cells.

In budding yeast, the simultaneous deletion of both GRX3 and GRX4 produces severe iron accumulation in the cytoplasm coupled with paradoxical iron-limited phenotypes affecting biosynthesis, directly establishing that these glutaredoxins function as critical iron distribution factors[2][9][14][38][39][43][46]. The defects in iron metabolism in grx3 grx4 double mutants result from combined activation of the transcriptional factor Aft1 through removal of GLRX3-mediated inhibition, and direct impairment of iron-sulfur cluster biogenesis for cytosolic proteins[2][9][14][38][39][43][46]. Aft1 is constitutively localized to the nucleus in grx3 grx4 mutants, causing continuous up-regulation of iron import genes and leading to toxic iron accumulation despite the cell's inability to incorporate this iron into iron-dependent proteins[2][9][38][39][43]. The heterologous expression of human GLRX3 in yeast grx3 grx4 double mutants efficiently complements the iron metabolism defects, demonstrating remarkable functional conservation despite the divergence of mammalian and yeast cell biology[2][9][43][46].

Yeast studies have also established the connection between monothiol glutaredoxins, guanine nucleotide metabolism, and cellular stress responses that appears conserved in higher organisms[2][9][14][38][43][46]. The discovery that GMP synthase interacts with both yeast Grx3/Grx4 and human GLRX3 through iron-sulfur cluster-dependent mechanisms revealed an unexpected coupling of iron metabolism to purine biosynthesis and integrated stress response pathways[2][9][14][38][43][46]. This connection suggests that cellular iron status is communicated to the biosynthetic machinery through the Glrx-GMP synthase complex, enabling cells to restrict biosynthesis when iron becomes limiting[2][9][14][38][43][46].

The study of GLRX3 in zebrafish development has provided critical insights into the in vivo significance of this protein for specific developmental processes, particularly hemoglobin maturation[8][11]. Grx3 depletion in zebrafish embryos impairs hemoglobin synthesis at a specific developmental window, establishing that GLRX3 is essential for the iron-dependent maturation of this critical protein[8][11]. These findings align perfectly with the human data demonstrating GLRX3's crucial role in supporting IRP1 maturation and maintaining appropriate iron distribution to hemoglobin synthesis pathways[8][11].

Conclusion

GLRX3, alternatively designated as PICOT (protein kinase C-interacting cousin of thioredoxin), has emerged as a multifunctional protein central to eukaryotic iron metabolism, cellular redox homeostasis, and stress response signaling. The distinctive three-domain architecture comprising an N-terminal thioredoxin-like domain and two C-terminal monothiol glutaredoxin domains positions GLRX3 as a sophisticated iron-sulfur cluster chaperone capable of coordinating, transferring, and reductively coupling [2Fe-2S] clusters into higher-order [4Fe-4S] cofactors essential for cytosolic protein maturation. Through multiple interlocking mechanisms, GLRX3 orchestrates the appropriate distribution of iron-sulfur clusters to target proteins including iron-regulatory protein 1, aconitase, ribonucleotide reductase, and DNA repair enzymes, thereby ensuring that iron supply is matched to biosynthetic demand and that iron-dependent enzymatic functions are appropriately maintained. The dynamic subcellular localization of GLRX3, shifting from predominantly cytoplasmic distribution under normal conditions to nuclear accumulation under oxidative stress, enables this protein to concentrate at sites requiring enhanced redox protection and iron-sulfur cluster availability. The integration of GLRX3 function into multiple signaling pathways including DNA damage response, protein kinase C signaling, epigenetic regulation through PRC2 interactions, and integrated stress response through GMP synthase collaboration establishes this protein as a central hub connecting iron metabolism to broader cellular regulatory networks. The frequent dysregulation of GLRX3 in multiple human malignancies, where increased expression correlates with poor prognosis and enhanced tumor progression, highlights the clinical relevance of understanding GLRX3 biology and suggests potential therapeutic opportunities through targeted modulation of this protein or its key interactions. The absolute developmental requirement for GLRX3, demonstrated through embryonic lethality of knockout mice and severe developmental abnormalities associated with GLRX3 mutations in human genetic disease, underscores the fundamental biological importance of this protein. Future investigations should focus on characterizing the precise mechanisms by which GLRX3 integrates iron sensing with epigenetic regulation and stress response signaling, identifying tissue-specific roles for GLRX3 beyond general iron metabolism, developing selective inhibitors or modulators of GLRX3 function for potential therapeutic applications in cancer and other diseases, and determining how dysregulation of GLRX3 in disease states can be therapeutically targeted. The emerging picture of GLRX3 as a sophisticated molecular switch coupling iron availability to biosynthetic capacity, stress responses, and epigenetic programming promises to yield important insights into the fundamental mechanisms connecting metabolism to gene regulation and cellular physiology throughout mammalian biology.

Citations

1. https://www.ncbi.nlm.nih.gov/gene/10539
2. https://journals.asm.org/doi/10.1128/AEM.00221-20
3. https://www.genecards.org/cgi-bin/carddisp.pl?gene=GLRX3
4. https://www.uniprot.org/uniprotkb/O76003/entry
5. https://www.nature.com/articles/s41419-019-1935-0
6. https://www.abcam.com/en-an/targets/glrx3/27096
7. https://pubs.acs.org/doi/10.1021/jacs.0c02266
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC3681695/
9. https://pubmed.ncbi.nlm.nih.gov/27519415/
10. https://pubmed.ncbi.nlm.nih.gov/23615448/
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC12375892/
12. https://www.uniprot.org/uniprotkb/A0A0G2K5P8/entry
13. https://pubmed.ncbi.nlm.nih.gov/29860757/
14. https://www.ncbi.nlm.nih.gov/gene/30926
15. https://pmc.ncbi.nlm.nih.gov/articles/PMC5077177/
16. https://stockton.primo.exlibrisgroup.com/discovery/fulldisplay?docid=cdi_pubmed_primary_29860757&context=PC&vid=01SUN_INST%3ASTOCKTON&lang=en&search_scope=MyInst_and_CI&adaptor=Primo+Central&tab=Everything&query=sub%2Cexact%2C+Neoplasm+Proteins+-+antagonists+%26+inhibitors+%2CAND&mode=advanced&offset=0
17. https://febs.onlinelibrary.wiley.com/doi/10.1002/1873-3468.70072
18. https://febs.onlinelibrary.wiley.com/doi/abs/10.1002/1873-3468.70072
19. https://pmc.ncbi.nlm.nih.gov/articles/PMC8007109/
20. https://pubmed.ncbi.nlm.nih.gov/26296460/
21. https://pmc.ncbi.nlm.nih.gov/articles/PMC7503856/
22. https://pmc.ncbi.nlm.nih.gov/articles/PMC5374299/
23. https://pubmed.ncbi.nlm.nih.gov/25975981/
24. https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2019.00712/pdf
25. https://pmc.ncbi.nlm.nih.gov/articles/PMC5095054/
26. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1496886/full
27. https://pubmed.ncbi.nlm.nih.gov/30595380/
28. https://pmc.ncbi.nlm.nih.gov/articles/PMC7763308/
29. https://pmc.ncbi.nlm.nih.gov/articles/PMC7357468/
30. https://www.pnas.org/doi/10.1073/pnas.2400740121
31. https://pmc.ncbi.nlm.nih.gov/articles/PMC7837452/
32. https://pubmed.ncbi.nlm.nih.gov/31176019/
33. https://pubmed.ncbi.nlm.nih.gov/32414791/
34. https://pmc.ncbi.nlm.nih.gov/articles/PMC8349188/
35. https://pubmed.ncbi.nlm.nih.gov/21034966/
36. https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=10539
37. https://www.ensembl.org/id/ENST00000368644
38. cellular needs[8][11][30]